the data also revealed 66% of trusts who replied had at least one cancer patient forced to wait over six months to start treatment, and 69% had a worse longest wait than in 2010.
.
.
.
fremanezumab has completed phase iii trials and is under review by the fda to prevent migraine and
.
/www.belfasttelegraph.co.uk/news/northern-ireland/article36918586.ece/6063c/autocrop/h342/2018-05-18_new_41038410_i2.jpg
.
.jeffrey krasner is president of emerging biocommunications, which consults to early- and mid-stage life science companies.
.